INSR and neoplasm: Targeting of all three receptors may be more efficient since dual inhibition of InsR and IGF1R with tyrosine kinase inhibitor OSI-906 in combination with ER downregulator fulvestrant more effectively suppress hormone-independent tumor growth than either drug alone (44).